# Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

> **NCT02652091** · — · COMPLETED · sponsor: **Bayer** · enrollment: 146 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Interferon beta-1b (Betaseron, BAY86-5046)
- **DEVICE:** BETACONNECT device

## Key facts

- **NCT ID:** NCT02652091
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-05
- **Primary completion:** 2017-08-11
- **Final completion:** 2017-09-13
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2018-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02652091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02652091, "Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02652091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*